Home / Antiviral
Antiviral peptides
Block the virus at the surface, with a peptide rather than an antibody.
Antiviral
Peptides that bind the virus and block entry
No approved drug exists for the treatment of COVID-19 patients outside the hospital setting. Repurposed drugs have shown some clinical benefit, but they have limitations, and are not approved to treat COVID-19 patients who are not hospitalized.
We are developing rapidly scalable, cost-effective technology which blocks COVID-19 infection by “binding” or attaching specifically to SARS-CoV-2 and blocking its entry into human cells. We believe the peptides (small proteins) we are studying act like antibodies or complements that our body naturally produces — binding to the SARS-CoV-2 virus, and targeting it for destruction.
The award
An NSF STTR Phase I
The project was supported by a Small Business Technology Transfer Phase I award from the National Science Foundation, to study how self-assembled peptides assemble on the surface of pathogens such as SARS-CoV-2 and what that does to infectivity and immune recognition.
We hope to create a safe and inexpensive therapeutic that will help reduce the spread and increase accessibility of treatment for COVID-19.
As awarded
- ProgrammeNSF STTR Phase I
- Award year2021
- Amount$255,933
- Contract2032392
- ProjectSelf-assembled peptides against SARS-CoV-2
- Principal investigatorCorey Heffernan
- Company statusHUBZone owned; socially and economically disadvantaged
The paper
Antiviral fibrils of self-assembled peptides with tunable compositions
Nature Communications, 7 February 2024
“The lasting threat of viral pandemics necessitates the development of tailorable first-response antivirals with specific but adaptive architectures for treatment of novel viral infections. Here, such an antiviral platform has been developed based on a mixture of hetero-peptides self-assembled into functionalized β-sheets capable of specific multivalent binding to viral protein complexes.”
Work with us
Protein-based therapeutics, translated
Saphtx works with academic inventors to translate engineered proteins toward the clinic. If you would like to work with the company, its inbox is public.